NCI Thesaurus OBO Edition
1112 terms(s) returned
| Term Type: | Record: 451 to 500 of 1112 Records | Page: 10 of 23, First Previous Next Last | Show Records Per Page |
- Warsaw Breakage Syndrome
- Warthin Tumor
- Warthin's Tumor of the Mouse Salivary Glands
- Warthin-Starry Staining Method
- Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome
- Warty (Bowenoid) Penile Intraepithelial Neoplasia
- Warty Carcinoma
- Warty Dyskeratoma
- Warty-Basaloid Penile Intraepithelial Neoplasia
- Was 10q23/PTEN Locus Deletion Analysis Performed
- Was 1p/19q Deletion Analysis Performed
- Was ALK Rearrangement Analysis Performed
- Was ATRX Mutation Analysis Performed
- Was Additional Immunohistochemical Testing Performed
- Was Additional Mutation Analysis Performed
- Was Additional Pharmaceutical Treatment for New Tumor Event Administered
- Was Additional Surgery for New Loco-Regional Tumor Event Performed
- Was Additional Surgery for New Metastatic Tumor Event Performed
- Was Additional Surgery for New Tumor Event Performed
- Was Additional Testing Performed
- Was Additional Treatment Administered for New Tumor Event
- Was Adjuvant I-131 Therapy Administered
- Was Adjuvant Post-Operative Chemotherapy Administered
- Was Adjuvant Post-Operative Hormone Therapy Administered
- Was Adjuvant Post-Operative Immunological Therapy Administered
- Was Adjuvant Post-Operative Pharmaceutical Therapy Administered
- Was Adjuvant Post-Operative Targeted Molecular Therapy Administered
- Was Adjuvant Post-operative Radiation Therapy Administered
- Was Another CD Antigen Tested
- Was BRAF Mutation Analysis Performed
- Was BRAF Rearrangement Analysis Performed
- Was Bone Marrow Transplantation Performed
- Was CSF Cytology Completed After Diagnosis
- Was CSF Cytology Completed at Diagnosis
- Was CSF Sample Positive for Tumor Cells
- Was Chemotherapy Administered as an Additional Treatment for a New Tumor Event
- Was EGFR Amplification Assessed
- Was EGFR Mutation Analysis Performed
- Was ERBB2 Mutation Analysis Performed
- Was Evidence of Disease Present after Completion of Therapy
- Was Fluorescence In Situ Hybridization Performed
- Was Hormone Therapy Administered as an Additional Treatment for a New Tumor Event
- Was Hydrocephalus Reported at Time of Diagnosis
- Was IDH Family Mutation Analysis Performed
- Was IV Anesthesia Administered
- Was Immunohistochemical Testing Performed
- Was Immunotherapy Administered
- Was Immunotherapy Administered as an Additional Treatment for a New Tumor Event
- Was In Situ Hybridization Performed
- Was Inhalation Anesthesia Administered
